Evidence map›Paper›PMID 31597673›Full record

ArticleGenetics2019

Distinct Functions in Regulation of Meiotic Crossovers for DNA Damage Response Clamp Loader Rad24(Rad17) and Mec1(ATR) Kinase.

Miki Shinohara, Douglas K Bishop, Akira Shinohara

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Phospho-Regulation of Meiotic Prophase.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Miki ShinoharaInstitute for Protein Research, Osaka University, 565-0871, Japan ashino@protein.osaka-u.ac.jp mikis@nara.kindai.ac.jp.ORCID 0000-0002-7413-8235
Douglas K BishopDepartment of Radiation Oncology, University of Chicago, Illinois 60637.ORCID 0000-0001-5061-8085
Akira ShinoharaInstitute for Protein Research, Osaka University, 565-0871, Japan ashino@protein.osaka-u.ac.jp mikis@nara.kindai.ac.jp.ORCID 0000-0003-4207-8247
Osaka University · JPProtein Research Foundation · JPUniversity of Chicago · US

Funding

MEIOTIC INTERACTIONS TO THE RECA HOMOLOGUE DMC1R01GM050936 · NIGMS · UNIVERSITY OF CHICAGO · PI BISHOP, DOUGLAS K · 1994 to 2019
$9.2M
NIGMS NIH HHS R01 GM050936
6 · The paper itself

Abstract

The number and distribution of meiotic crossovers (COs) are highly regulated, reflecting the requirement for COs during the first round of meiotic chromosome segregation. CO control includes CO assurance and CO interference, which promote at least one CO per chromosome bivalent and evenly-spaced COs, respectively. Previous studies revealed a role for the DNA damage response (DDR) clamp and the clamp loader in CO formation by promoting interfering COs and interhomolog recombination, and also by suppressing ectopic recombination. In this study, we use classical tetrad analysis of

Indexed as

Crossing Over, GeneticCell Cycle ProteinsChromosome SegregationChromosomes, FungalDNA-Binding ProteinsDNA DamageIntracellular Signaling Peptides and ProteinsMeiosisMutationNuclear ProteinsProtein Serine-Threonine KinasesRecombination, GeneticSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsCell Cycle ProteinsDNA-Binding ProteinsIntracellular Signaling Peptides and ProteinsMEC1 protein, S cerevisiaeNuclear ProteinsProtein Serine-Threonine KinasesRAD17 protein, S cerevisiaeSaccharomyces cerevisiae Proteinscrossover interferencecrossoversMec1meiosisRad24

Identifiers

PMID31597673
PMCPMC6893372
OpenAlexW2979874571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.